52. Boccardo F,Amoroso D. Management of breast cancer:Is there a role for somatostatin and its analogs? Chemotherapy 2001;47 Suppl 2:62-77. Abstract

53. Boehm T et al. Anti-angiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997;390:404. Abstract

54. Gasparini G. Clinical significance of determination of surrogate markers of angiogenesis in breast cancer. Crit Rev Oncol Hematol 2001;37:97-114. Abstract

55. Gasparini G et al. Angiogenesis sustains tumor dormancy in patients with breast cancer treated with adjuvant chemotherapy. Breast Cancer Res Treat 2001;65(1):71-5. Abstract

56. Li C et al. Angiogenesis in breast cancer:The role of transforming growth factor beta and CD105. Microsc Res Tech 2001;52:437-49. Abstract

57. Losordo DW ,Isner JM. Estrogen and angiogenesis: A review. Arterioscler Thromb Vasc Biol 2001;21:6-12. Abstract

58. Miller KD et al. Redefining the target:Chemotherapeutics as anti-angiogenics. J Clin Oncol 2001;19(4):1195-1206. Abstract

59.O ’Reilly MS et al. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 1996;2:689. Abstract

60. Saaristo A et al. Mechanisms of angiogenesis and their use in the inhibition of tumor growth and metastasis. Oncogene 2000;19:6122-9. Abstract

61.Toi M et al. The predictive value of angiogenesis for adjuvant therapy in breast cancer. Breast Cancer 2000;7:311-4. Abstract

62.Tung-Ping Poon R et al. Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol 2001;19(4):1207-1225. Abstract

OTHER RESOURCES

Angiogenesis Foundation: An Organization to Facilitate the Development and Application of Angiogenesis-based Medicine Web link

Three-Dimensional Simulation of Angiogenesis Web link

International Peer-Reviewed Journal:Angiogenesis Web link

NCI Cancer Facts for Patients:Angiogenesis Inhibitors in the Treatment of Cancer Web link

NCI Listing:Angiogenesis Inhbitors in Clinical Trials Web link